Skip to main content
. Author manuscript; available in PMC: 2010 Jun 1.
Published in final edited form as: Clin Cancer Res. 2009 Nov 24;15(23):7144–7152. doi: 10.1158/1078-0432.CCR-09-1483

Figure 4. mAb 1339 enhances growth inhibitory effect of anti-MM agents in the context of BMSC.

Figure 4

INA-6 and MM1S cells were cultured with BMSC in the absence or presence of mAb 1339 (1 μg/ml) and dexamethasone (1 μM), velcade (5nM), perifosine (2.5 μM), revlimid (5 μM) with (1 μg/ml) or without mAb 1339 for 48 hours. DNA synthesis was assessed by [3H] thymidine uptake assay and presented as % of control cells without mAb 1339 or other agents. Data represent mean +/- SD, (N=3). The combination of mAb 1339 and other anti-MM agents resulted in significant (p < 0.05) and synergistic antiproliferative effect.